7 May 2025

ProBiotix Health plc

("ProBiotix" or the "Company" or, together with its subsidiary, the "Group")

Notice of Results and Investor Presentation

ProBiotix Health plc (AQSE: PBX), the life sciences business developing probiotics to support cardiometabolic health, today confirms that it will release its audited results for the year ended 31 December 2024 on Thursday, 29 May 2025.

Investor Presentation

Steen Andersen, Chief Executive, and Mark Collingbourne, Chief Finance Officer, will host a presentation at 10:00 am on the day of the results. It will be open to all existing and potential shareholders and will provide the opportunity for investors to listen to management discuss the Group's full year results. Questions can be submitted in advance of the presentation, via the Investor Meet Company dashboard, up until 9:00 am on the day of the meeting, or any time during the live presentation.

To sign up to the presentation via Investor Meet Company please register using the following link: https://www.investormeetcompany.com/probiotix-health-plc/register-investor

For further information, please contact:

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

Notes to Editors:

ProBiotix is a life sciences company that develops probiotic formulations to support cardiometabolic health. Since its formation, ProBiotix has become recognised as a global leader in microbiome modulating probiotics for use in food supplements and nutraceuticals.

The Company has a unique approach: discovering ground breaking probiotics, ensuring their benefits through robust science, and bringing to market effective finished probiotic-based products for human health across the globe.